Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » GenMark Diagnostics, Chembio Diagnostics Price Stock Offerings

GenMark Diagnostics, Chembio Diagnostics Price Stock Offerings

May 07, 2020
|
staff reporter

NEW YORK ─ GenMark Diagnostics said Wednesday that it has priced an approximately $70 million public offering of its common stock. Separately, Chembio Diagnostics said it has priced a $27.5 million offering of its common stock.

Carlsbad, California-based GenMark said it expects to sell 7,253,886 shares at $9.65 per share. It has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,088,082 shares at the public offering price, less underwriting discounts and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Millions of Tests

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Court Pick and Science

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Arthur Ashkin Dies

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

PNAS Papers on Alzheimer's Transcriptomes, Bladder Cancer Mutations, CRC Drivers

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

Sponsored by
Agena Bioscience

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

What's Popular?

In Molecular Diagnostics

  1. Fluidigm Finalizes $34M NIH Contract for SARS-CoV-2 Assay Production

  2. Swift Biosciences, BillionToOne Partner to Commercialize COVID-19 Test

  3. NIH Awards Two SBIR Grants Totaling $3.9M to Phase Genomics

  4. Angle Files De Novo FDA Submission for CTC Collection Device in Breast Cancer

  5. Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.